Search research articles
Contact Us
Filters
Showing results (31-40 of 393) with videos related to
Page
of 40
Sort By:
Cancers
|
December 23, 2018
Optimising Cancer Vaccine Design in Sarcoma
Alexandra Pender, Robin L Jones, Seth Pollack
Expert Opinion on Drug Safety
|
May 6, 2021
Managing the risk of toxicity in the treatment of elderly patients with soft tissue sarcomas
Samia Arifi, Anastasia Constantinidou, Robin L Jones
Frontiers in Oncology
|
April 8, 2020
The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives
Stavros Gkolfinopoulos, Robin L Jones, Anastasia Constantinidou
Future Oncology (London, England)
|
November 4, 2021
Dedifferentiated chondrosarcoma: current standards of care
Abhay K Kattepur, Robin L Jones, Aashish Gulia
Oncotargets and Therapy
|
March 26, 2013
Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
Rajeev Rajendra, Robin L Jones, Seth M Pollack
Future Oncology (London, England)
|
February 19, 2013
Management of gastrointestinal stromal tumors
Rajeev Rajendra, Seth M Pollack, Robin L Jones
The Lancet. Oncology
|
October 23, 2012
MDM2 inhibition in liposarcoma: a step in the right direction
Anastasia Constantinidou, Seth M Pollack, Robin L Jones
Gynecologic Oncology
|
December 17, 2013
Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth
Brett Schroeder, Seth M Pollack, Robin L Jones
Expert Opinion on Pharmacotherapy
|
August 11, 2015
Current and advancing systemic treatment options for soft tissue sarcomas
Samuel J Harris, Charlotte Benson, Robin L Jones
Expert Review of Clinical Pharmacology
|
February 14, 2016
Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options
Florence Duffaud, Robert G Maki, Robin L Jones
Page
of 40
Search research articles
Search
Showing results (31-40 of 393) with videos related to
Sort By:
Page
of 40
Cancers
|
December 23, 2018
Optimising Cancer Vaccine Design in Sarcoma
Alexandra Pender, Robin L Jones, Seth Pollack
Expert Opinion on Drug Safety
|
May 6, 2021
Managing the risk of toxicity in the treatment of elderly patients with soft tissue sarcomas
Samia Arifi, Anastasia Constantinidou, Robin L Jones
Frontiers in Oncology
|
April 8, 2020
The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives
Stavros Gkolfinopoulos, Robin L Jones, Anastasia Constantinidou
Future Oncology (London, England)
|
November 4, 2021
Dedifferentiated chondrosarcoma: current standards of care
Abhay K Kattepur, Robin L Jones, Aashish Gulia
Oncotargets and Therapy
|
March 26, 2013
Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
Rajeev Rajendra, Robin L Jones, Seth M Pollack
Future Oncology (London, England)
|
February 19, 2013
Management of gastrointestinal stromal tumors
Rajeev Rajendra, Seth M Pollack, Robin L Jones
The Lancet. Oncology
|
October 23, 2012
MDM2 inhibition in liposarcoma: a step in the right direction
Anastasia Constantinidou, Seth M Pollack, Robin L Jones
Gynecologic Oncology
|
December 17, 2013
Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth
Brett Schroeder, Seth M Pollack, Robin L Jones
Expert Opinion on Pharmacotherapy
|
August 11, 2015
Current and advancing systemic treatment options for soft tissue sarcomas
Samuel J Harris, Charlotte Benson, Robin L Jones
Expert Review of Clinical Pharmacology
|
February 14, 2016
Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options
Florence Duffaud, Robert G Maki, Robin L Jones
Page
of 40